{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T13:34:06Z","timestamp":1782567246942,"version":"3.54.5"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"DOI":"10.1007\/s00404-022-06549-6","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T03:30:03Z","timestamp":1650252603000},"page":"1347-1376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of pharmacological interventions on biochemical hyperandrogenemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1007","volume":"307","author":[{"given":"Mohammed Altigani","family":"Abdalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najeeb","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshal","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"\u00d6stlundh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami H.","family":"Al-Rifai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Atkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3544-2231","authenticated-orcid":false,"given":"Thozhukat","family":"Sathyapalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"key":"6549_CR1","doi-asserted-by":"publisher","first-page":"118174","DOI":"10.1016\/j.lfs.2020.118174","volume":"259","author":"M Abdalla","year":"2020","unstructured":"Abdalla M, Deshmukh H, Atkin SL, Sathyapalan T (2020) miRNAs as a novel clinical biomarker and therapeutic targets in polycystic ovary syndrome (PCOS): a review. Life Sci. 259:118174","journal-title":"Life Sci."},{"issue":"4","key":"6549_CR2","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1111\/jcmm.16205","volume":"25","author":"W Ye","year":"2021","unstructured":"Ye W, Xie T, Song Y, Zhou L (2021) The role of androgen and its related signals in PCOS. J Cell Mol Med 25(4):1825\u20131837","journal-title":"J Cell Mol Med"},{"key":"6549_CR3","doi-asserted-by":"publisher","first-page":"652559","DOI":"10.3389\/fphys.2021.652559","volume":"12","author":"MA Abdalla","year":"2021","unstructured":"Abdalla MA, Deshmukh H, Mohammed I, Atkin S, Reid M, Sathyapalan T (2021) The effect of free androgen index on the quality of life of women with polycystic ovary syndrome: a cross-sectional study. Front Physiol 12:652559","journal-title":"Front Physiol"},{"issue":"5","key":"6549_CR4","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1210\/er.2015-1104","volume":"37","author":"RL Rosenfield","year":"2016","unstructured":"Rosenfield RL, Ehrmann DA (2016) The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev 37(5):467\u2013520","journal-title":"Endocr Rev"},{"key":"6549_CR5","doi-asserted-by":"publisher","first-page":"105752","DOI":"10.1016\/j.jsbmb.2020.105752","volume":"204","author":"T Li","year":"2020","unstructured":"Li T, Zhang T, Cui T et al (2020) Involvement of endogenous testosterone in hepatic steatosis in women with polycystic ovarian syndrome. J Steroid Biochem Mol Biol 204:105752","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"15","key":"6549_CR6","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.3390\/ijms21155342","volume":"21","author":"M Grymowicz","year":"2020","unstructured":"Grymowicz M, Rudnicka E, Podfigurna A et al (2020) Hormonal effects on hair follicles. Int J Mol Sci 21(15):5342","journal-title":"Int J Mol Sci"},{"issue":"2","key":"6549_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/17446651.2019.1576522","volume":"14","author":"DH Abbott","year":"2019","unstructured":"Abbott DH, Dumesic DA, Levine JE (2019) Hyperandrogenic origins of polycystic ovary syndrome - implications for pathophysiology and therapy. Expert Rev Endocrinol Metab 14(2):131\u2013143","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"4","key":"6549_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.5455\/medarh.2020.74.289-293","volume":"74","author":"Z Saadia","year":"2020","unstructured":"Saadia Z (2020) Follicle stimulating hormone (LH: FSH) ratio in polycystic ovary syndrome (PCOS) - obese vs. non- obese women. Med Arch 74(4):289\u2013293","journal-title":"Med Arch"},{"issue":"5","key":"6549_CR9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1080\/19396368.2019.1595217","volume":"65","author":"R Deswal","year":"2019","unstructured":"Deswal R, Nanda S, Dang AS (2019) Association of luteinizing hormone and LH receptor gene polymorphism with susceptibility of polycystic ovary syndrome. Syst Biol Reprod Med 65(5):400\u2013408","journal-title":"Syst Biol Reprod Med"},{"issue":"1","key":"6549_CR10","doi-asserted-by":"publisher","first-page":"hoy021","DOI":"10.1093\/hropen\/hoy021","volume":"2019","author":"MF Costello","year":"2019","unstructured":"Costello MF, Misso ML, Balen A et al (2019) Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: assessment and treatment of infertility. Hum Reprod Open 2019(1):hoy021","journal-title":"Hum Reprod Open"},{"key":"6549_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/IJWH.S11304","volume":"3","author":"A Badawy","year":"2011","unstructured":"Badawy A, Elnashar A (2011) Treatment options for polycystic ovary syndrome. Int J Womens Health 3:25\u201335","journal-title":"Int J Womens Health"},{"key":"6549_CR12","doi-asserted-by":"publisher","first-page":"204201882093830","DOI":"10.1177\/2042018820938305","volume":"11","author":"MA Abdalla","year":"2020","unstructured":"Abdalla MA, Deshmukh H, Atkin S, Sathyapalan T (2020) A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Ther Adv Endocrinol Metab 11:2042018820938305","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"5","key":"6549_CR13","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S0090-4295(03)00661-7","volume":"62","author":"CG Roehrborn","year":"2003","unstructured":"Roehrborn CG, Lee M, Meehan A, Waldstreicher J, Group PS (2003) Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology 62(5):894\u2013899","journal-title":"Urology"},{"issue":"6","key":"6549_CR14","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1210\/er.2011-1034","volume":"33","author":"E Diamanti-Kandarakis","year":"2012","unstructured":"Diamanti-Kandarakis E, Dunaif A (2012) Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33(6):981\u20131030","journal-title":"Endocr Rev"},{"issue":"8","key":"6549_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.tem.2003.08.002","volume":"14","author":"S Sam","year":"2003","unstructured":"Sam S, Dunaif A (2003) Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 14(8):365\u2013370","journal-title":"Trends Endocrinol Metab"},{"key":"6549_CR16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"6549_CR17","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.15167373.v1","author":"MA Abdalla","year":"2021","unstructured":"Abdalla MA, Shah N, Deshmukh H, Sahebkar A, Al-Rifai RH, Atkin SL et al (2021) Impact of pharmacological Interventions on biochemical hyperandrogenaemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials, figshare. Figure. https:\/\/doi.org\/10.6084\/m9.figshare.15167373.v1","journal-title":"Figure"},{"issue":"2","key":"6549_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4103\/IJPSYM.IJPSYM_290_17","volume":"40","author":"S Das","year":"2018","unstructured":"Das S, Chatterjee SS (2018) Cabell\u2019s blacklist: a new way to tackle predatory journals. Indian J Psychol Med 40(2):197\u2013198","journal-title":"Indian J Psychol Med"},{"issue":"2","key":"6549_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5596\/c14-016","volume":"35","author":"J Babineau","year":"2014","unstructured":"Babineau J (2014) Product review: covidence (systematic review software). J Can Health Libr Assoc\/Journal de l\u2019Association des biblioth\u00e8ques de la sant\u00e9 du Canada 35(2):68\u201371","journal-title":"J Can Health Libr Assoc\/Journal de l'Association des biblioth\u00e8ques de la sant\u00e9 du Canada"},{"key":"6549_CR20","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC et al (2011) The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:928","journal-title":"BMJ"},{"key":"6549_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JP Higgins","year":"2019","unstructured":"Higgins JP, Thomas J, Chandler J et al (2019) Cochrane handbook for systematic reviews of interventions. John Wiley and Sons"},{"issue":"7650","key":"6549_CR22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926","journal-title":"BMJ"},{"issue":"6","key":"6549_CR23","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/S0015-0282(02)03101-1","volume":"77","author":"S Ajossa","year":"2002","unstructured":"Ajossa S, Guerriero S, Paoletti AM, Orr\u00f9 M, Melis GB (2002) The antiandrogenic effect of flutamide improves uterine perfusion in women with polycystic ovary syndrome. Fertil Steril 77(6):1136\u20131140","journal-title":"Fertil Steril"},{"issue":"4","key":"6549_CR24","first-page":"205","volume":"15","author":"M Amiri","year":"2014","unstructured":"Amiri M, Golsorkhtabaramiri M, Esmaeilzadeh S et al (2014) Effect of metformin and flutamide on anthropometric indices and laboratory tests in obese\/overweight PCOS women under hypocaloric diet. J Reprod Infertil 15(4):205\u2013213","journal-title":"J Reprod Infertil"},{"issue":"2","key":"6549_CR25","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1210\/jc.2006-1988","volume":"92","author":"B Banaszewska","year":"2007","unstructured":"Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ (2007) Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, cross-over trial. J Clin Endocrinol Metab 92(2):456\u2013461","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6549_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijgo.2015.06.065","volume":"132","author":"SM Bhattacharya","year":"2016","unstructured":"Bhattacharya SM, Jha A, DasMukhopadhyay L (2016) Comparison of two contraceptive pills containing drospirenone and 20 \u03bcg or 30 \u03bcg ethinyl estradiol for polycystic ovary syndrome. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet 132(2):210\u2013213","journal-title":"Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet"},{"issue":"14","key":"6549_CR27","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2169\/internalmedicine.48.2177","volume":"48","author":"O Bilgir","year":"2009","unstructured":"Bilgir O, Kebapcilar L, Taner C et al (2009) The effect of ethinylestradiol (EE)\/cyproterone acetate (CA) and EE\/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). Intern Med (Tokyo, Japan) 48(14):1193\u20131199","journal-title":"Intern Med (Tokyo, Japan)"},{"issue":"7","key":"6549_CR28","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1093\/humrep\/dep074","volume":"24","author":"SM Carlsen","year":"2009","unstructured":"Carlsen SM, Vanky E, Fleming R (2009) Anti-M\u00fcllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Human Reprod (Oxford, England) 24(7):1732\u20131738","journal-title":"Human Reprod (Oxford, England)"},{"issue":"3","key":"6549_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/TEN.0b013e3181a58772","volume":"19","author":"S Cetinkalp","year":"2009","unstructured":"Cetinkalp S, Karadeniz M, Erdogan M, Ozgen G, Saygl F, Ylmaz C (2009) The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist 19(3):94\u201397","journal-title":"Endocrinologist"},{"issue":"2","key":"6549_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1365-2265.2008.03309.x","volume":"70","author":"LW Cho","year":"2009","unstructured":"Cho LW, Kilpatrick ES, Keevil BG, Coady AM, Atkin SL (2009) Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol 70(2):233\u2013237","journal-title":"Clin Endocrinol"},{"issue":"1","key":"6549_CR31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1210\/clinem\/dgz028","volume":"105","author":"JK Devin","year":"2020","unstructured":"Devin JK, Nian H, Celedonio JE, Wright P, Brown NJ (2020) Sitagliptin decreases visceral fat and blood glucose in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 105(1):136","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"6549_CR32","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1210\/jc.2005-1994","volume":"91","author":"S Eisenhardt","year":"2006","unstructured":"Eisenhardt S, Schwarzmann N, Henschel V et al (2006) Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 91(3):946\u2013952","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"6549_CR33","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1210\/jc.2008-0115","volume":"93","author":"K Elkind-Hirsch","year":"2008","unstructured":"Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R (2008) Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 93(7):2670\u20132678","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"6549_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s13224-017-1022-3","volume":"67","author":"MAM Elsersy","year":"2017","unstructured":"Elsersy MAM (2017) Efficacy of combined cabergoline and metformin compared to metformin alone on cycle regularity in patients with polycystic ovarian disease with hyperprolactinemia: a randomized clinical trial. J Obstet Gynaecol India 67(5):363\u2013369","journal-title":"J Obstet Gynaecol India"},{"issue":"1","key":"6549_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4158\/EP-2017-0027","volume":"24","author":"S Ferjan","year":"2018","unstructured":"Ferjan S, Janez A, Jensterle M (2018) DPP4 inhibitor sitagliptin as a potential treatment option in metformin-intolerant obese women with polycystic ovary syndrome: a pilot randomized study. Endocr Pract: Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 24(1):69\u201377","journal-title":"Endocr Pract: Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"issue":"10","key":"6549_CR36","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1210\/jc.2005-2250","volume":"91","author":"A Gambineri","year":"2006","unstructured":"Gambineri A, Patton L, Vaccina A et al (2006) Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 91(10):3970\u20133980","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"6549_CR37","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1210\/jc.2014-1135","volume":"99","author":"D Glintborg","year":"2014","unstructured":"Glintborg D, Altinok ML, Mumm H, Hermann AP, Ravn P, Andersen M (2014) Body composition is improved during 12 months\u2019 treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metab 99(7):2584\u20132591","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6549_CR38","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1530\/EC-17-0034","volume":"6","author":"D Glintborg","year":"2017","unstructured":"Glintborg D, Mumm H, Holst JJ, Andersen M (2017) Effect of oral contraceptives and\/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome. Endocr Connect 6(4):267\u2013277","journal-title":"Endocr Connect"},{"issue":"9","key":"6549_CR39","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3109\/09513591003686379","volume":"26","author":"A Hanjalic-Beck","year":"2010","unstructured":"Hanjalic-Beck A, Gabriel B, Schaefer W et al (2010) Metformin versus acarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study. Gynecol Endocrinol: Off J Int Soc Gynecol Endocrinol 26(9):690\u2013697","journal-title":"Gynecol Endocrinol: Off J Int Soc Gynecol Endocrinol"},{"issue":"12","key":"6549_CR40","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/j.mayocp.2019.06.015","volume":"94","author":"B Heidari","year":"2019","unstructured":"Heidari B, Lerman A, Lalia AZ, Lerman LO, Chang AY (2019) Effect of metformin on microvascular endothelial function in polycystic ovary syndrome. Mayo Clin Proc 94(12):2455\u20132466","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"6549_CR41","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3892\/etm.2016.3081","volume":"11","author":"M Jensterle","year":"2016","unstructured":"Jensterle M, Goricar K, Janez A (2016) Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: randomized control study. Exp Ther Med 11(4):1194\u20131200","journal-title":"Exp Ther Med"},{"issue":"6","key":"6549_CR42","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1016\/j.fertnstert.2009.11.045","volume":"94","author":"T Kazerooni","year":"2010","unstructured":"Kazerooni T, Shojaei-Baghini A, Dehbashi S, Asadi N, Ghaffarpasand F, Kazerooni Y (2010) Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. Fertil Steril 94(6):2208\u20132213","journal-title":"Fertil Steril"},{"issue":"3","key":"6549_CR43","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00404-009-1189-7","volume":"281","author":"L Kebapcilar","year":"2010","unstructured":"Kebapcilar L, Bilgir O, Taner CE et al (2010) Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients. Arch Gynecol Obstet 281(3):539\u2013543","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"6549_CR44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00404-009-1051-y","volume":"281","author":"L Kebapcilar","year":"2010","unstructured":"Kebapcilar L, Taner CE, Kebapcilar AG, Alacacioglu A, Sari I (2010) Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Arch Gynecol Obstet 281(1):35\u201342","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"6549_CR45","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.fertnstert.2011.05.085","volume":"96","author":"PM Lam","year":"2011","unstructured":"Lam PM, Tam WH, Ma RC et al (2011) The reproductive and metabolic effect of rosiglitazone on Chinese women with polycystic ovarian syndrome\u2013a double-blind randomized placebo-controlled study. Fertil Steril 96(2):445-451.e441","journal-title":"Fertil Steril"},{"issue":"3","key":"6549_CR46","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/jog.12543","volume":"41","author":"S Leelaphiwat","year":"2015","unstructured":"Leelaphiwat S, Jongwutiwes T, Lertvikool S et al (2015) Comparison of desogestrel\/ethinyl estradiol plus spironolactone versus cyproterone acetate\/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial. J Obstet Gynaecol Res 41(3):402\u2013410","journal-title":"J Obstet Gynaecol Res"},{"issue":"1","key":"6549_CR47","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.fertnstert.2019.09.011","volume":"113","author":"Y Li","year":"2020","unstructured":"Li Y, Tan J, Wang Q, Duan C, Hu Y, Huang W (2020) Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril 113(1):197\u2013204","journal-title":"Fertil Steril"},{"issue":"2","key":"6549_CR48","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3109\/01443615.2012.745839","volume":"33","author":"L Mohiyiddeen","year":"2013","unstructured":"Mohiyiddeen L, Watson AJ, Apostolopoulos NV, Berry R, Alexandraki KI, Jude EB (2013) Effects of low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical outcomes in polycystic ovary syndrome. J Obstet Gynaecol: J Inst Obstet Gynaecol 33(2):165\u2013170","journal-title":"J Obstet Gynaecol: J Inst Obstet Gynaecol"},{"issue":"12","key":"6549_CR49","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1210\/jc.2013-2674","volume":"98","author":"J Puurunen","year":"2013","unstructured":"Puurunen J, Piltonen T, Puukka K et al (2013) Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 98(12):4798\u20134807","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"6549_CR50","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/BF03346756","volume":"36","author":"D Romualdi","year":"2013","unstructured":"Romualdi D, De Cicco S, Busacca M, Gagliano D, Lanzone A, Guido M (2013) Clinical efficacy and metabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: a randomized study. J Endocrinol Invest 36(8):636\u2013641","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"6549_CR51","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/j.fertnstert.2009.01.114","volume":"93","author":"D Romualdi","year":"2010","unstructured":"Romualdi D, Giuliani M, Cristello F et al (2010) Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Fertil Steril 93(7):2303\u20132310","journal-title":"Fertil Steril"},{"key":"6549_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogoh.2018.10.006","author":"A Sahu","year":"2018","unstructured":"Sahu A, Tripathy P, Mohanty J, Nagy A (2018) Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: a randomized controlled trial. J Gynecol Obstet Human Reprod. https:\/\/doi.org\/10.1016\/j.jogoh.2018.10.006","journal-title":"J Gynecol Obstet Human Reprod"},{"issue":"1","key":"6549_CR53","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1210\/jc.2008-1750","volume":"94","author":"T Sathyapalan","year":"2009","unstructured":"Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL (2009) The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab 94(1):103\u2013108","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"6549_CR54","doi-asserted-by":"publisher","first-page":"805","DOI":"10.4103\/2230-8210.192925","volume":"20","author":"K Shahebrahimi","year":"2016","unstructured":"Shahebrahimi K, Jalilian N, Bazgir N, Rezaei M (2016) Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome. Indian J Endocrinol Metab 20(6):805\u2013809","journal-title":"Indian J Endocrinol Metab"},{"issue":"12","key":"6549_CR55","first-page":"743","volume":"14","author":"SM Sohrevardi","year":"2016","unstructured":"Sohrevardi SM, Nosouhi F, Hossein Khalilzade S et al (2016) Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: an RCT. Int J Reprod Biomed (Yazd, Iran) 14(12):743\u2013754","journal-title":"Int J Reprod Biomed (Yazd, Iran)"},{"issue":"2","key":"6549_CR56","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.fertnstert.2012.10.013","volume":"99","author":"H Sova","year":"2013","unstructured":"Sova H, Puistola U, Morin-Papunen L, Karihtala P (2013) Metformin decreases serum 8-hydroxy-2\u2019-deoxyguanosine levels in polycystic ovary syndrome. Fertil Steril 99(2):593\u2013598","journal-title":"Fertil Steril"},{"issue":"3","key":"6549_CR57","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/humrep\/deh103","volume":"19","author":"E Vanky","year":"2004","unstructured":"Vanky E, Salvesen KA, Carlsen SM (2004) Six-month treatment with low-dose dexamethasone further reduces androgen levels in PCOS women treated with diet and lifestyle advice, and metformin. Human Reprod (Oxford, England) 19(3):529\u2013533","journal-title":"Human Reprod (Oxford, England)"},{"issue":"8","key":"6549_CR58","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/humrep\/deh347","volume":"19","author":"E Vanky","year":"2004","unstructured":"Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM (2004) Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Human Reprod (Oxford, England) 19(8):1734\u20131740","journal-title":"Human Reprod (Oxford, England)"},{"issue":"7","key":"6549_CR59","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/09513590802217027","volume":"24","author":"J Wu","year":"2008","unstructured":"Wu J, Zhu Y, Jiang Y, Cao Y (2008) Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecol Endocrinol: Off J Int Soc Gynecol Endocrinol 24(7):392\u2013398","journal-title":"Gynecol Endocrinol: Off J Int Soc Gynecol Endocrinol"},{"issue":"3","key":"6549_CR60","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1080\/09513590500231627","volume":"21","author":"M Yilmaz","year":"2005","unstructured":"Yilmaz M, Karako\u00e7 A, T\u00f6r\u00fcner FB et al (2005) The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol: Off J Int Soc Gynecol Endocrinol 21(3):154\u2013160","journal-title":"Gynecol Endocrinol: Off J Int Soc Gynecol Endocrinol"},{"issue":"2","key":"6549_CR61","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.fertnstert.2007.12.002","volume":"91","author":"MM Zain","year":"2009","unstructured":"Zain MM, Jamaluddin R, Ibrahim A, Norman RJ (2009) Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril 91(2):514\u2013521","journal-title":"Fertil Steril"},{"issue":"1","key":"6549_CR62","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","volume":"81","author":"Rotterdam EA-SPCWG","year":"2004","unstructured":"Rotterdam EA-SPCWG (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 81(1):19\u201325","journal-title":"Fertil Steril."},{"issue":"1","key":"6549_CR63","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/humrep\/dez255","volume":"35","author":"M Amiri","year":"2020","unstructured":"Amiri M, Nahidi F, Bidhendi-Yarandi R, Khalili D, Tohidi M, Ramezani TF (2020) A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a cross-over randomized controlled trial. Human Reprod (Oxford, England) 35(1):175\u2013186","journal-title":"Human Reprod (Oxford, England)"},{"issue":"3","key":"6549_CR64","doi-asserted-by":"publisher","first-page":"283","DOI":"10.6061\/clinics\/2012(03)14","volume":"67","author":"JG Batista","year":"2012","unstructured":"Batista JG, Soares JM, Maganhin CC, Sim\u00f5es RS, Tomaz G, Baracat EC (2012) Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study. Clinics (Sao Paulo, Brazil) 67(3):283\u2013287","journal-title":"Clinics (Sao Paulo, Brazil)"},{"issue":"2","key":"6549_CR65","first-page":"93","volume":"13","author":"A Ghaneei","year":"2015","unstructured":"Ghaneei A, Jowkar A, Hasani Ghavam MR, Ghaneei ME (2015) Cabergoline plus metformin therapy effects on menstrual irregularity and androgen system in polycystic ovary syndrome women with hyperprolactinemia. Iran J Reprod Med 13(2):93\u2013100","journal-title":"Iran J Reprod Med"},{"issue":"2","key":"6549_CR66","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","volume":"91","author":"R Azziz","year":"2009","unstructured":"Azziz R, Carmina E, Dewailly D et al (2009) The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91(2):456\u2013488","journal-title":"Fertil Steril"},{"issue":"1","key":"6549_CR67","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.dsx.2007.12.003","volume":"2","author":"J Ahmad","year":"2008","unstructured":"Ahmad J, Shukla N, Khan AR, Ahmed F, Siddiqui MA (2008) Comparison of metabolic effects of metformin and rosiglitazone in the management of polycystic ovary syndrome (PCOS): a prospective, parallel, randomized, open-label study. Diabetes Metab Syndr Clin Res Rev 2(1):37\u201346","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"2","key":"6549_CR68","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1210\/jc.2008-1133","volume":"94","author":"VR Aroda","year":"2009","unstructured":"Aroda VR, Ciaraldi TP, Burke P et al (2009) Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab 94(2):469\u2013476","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6549_CR69","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.fertnstert.2016.09.023","volume":"107","author":"KE Elkind-Hirsch","year":"2017","unstructured":"Elkind-Hirsch KE, Paterson MS, Seidemann EL, Gutowski HC (2017) Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin\/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot. Fertil Steril 107(1):253-260.e251","journal-title":"Fertil Steril"},{"issue":"6","key":"6549_CR70","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1530\/EJE-07-0857","volume":"158","author":"M Jensterle","year":"2008","unstructured":"Jensterle M, Janez A, Mlinar B, Marc J, Prezelj J, Pfeifer M (2008) Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. Eur J Endocrinol 158(6):793\u2013801","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"6549_CR71","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF03401383","volume":"14","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A (2015) A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens) 14(1):81\u201390","journal-title":"Hormones (Athens)"},{"issue":"4","key":"6549_CR72","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-08-0507","volume":"159","author":"M Jensterle","year":"2008","unstructured":"Jensterle M, Sebestjen M, Janez A et al (2008) Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. Eur J Endocrinol 159(4):399\u2013406","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"6549_CR73","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-13-0797","volume":"170","author":"M Jensterle Sever","year":"2014","unstructured":"Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A (2014) Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol 170(3):451\u2013459","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"6549_CR74","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3109\/09513590.2010.507283","volume":"27","author":"D Panidis","year":"2011","unstructured":"Panidis D, Georgopoulos NA, Piouka A et al (2011) The impact of oral contraceptives and metformin on anti-M\u00fcllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecol Endocrinol: Off J Int Soc Gynecol Endocrinol 27(8):587\u2013592","journal-title":"Gynecol Endocrinol: Off J Int Soc Gynecol Endocrinol"},{"issue":"9","key":"6549_CR75","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1093\/humrep\/dei104","volume":"20","author":"IA Penna","year":"2005","unstructured":"Penna IA, Canella PR, Reis RM, de S\u00e1 MFS, Ferriani RA (2005) Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. Human Reprod (Oxford, England). 20(9):2396\u20132401","journal-title":"Human Reprod (Oxford, England)."},{"issue":"1","key":"6549_CR76","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.fertnstert.2008.09.034","volume":"93","author":"HJ Teede","year":"2010","unstructured":"Teede HJ, Meyer C, Hutchison SK, Zoungas S, McGrath BP, Moran LJ (2010) Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. Fertil Steril 93(1):184\u2013191","journal-title":"Fertil Steril"},{"issue":"1","key":"6549_CR77","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/humrep\/deh580","volume":"20","author":"AS S\u00f6nmez","year":"2005","unstructured":"S\u00f6nmez AS, Yasar L, Savan K et al (2005) Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. Human Reprod (Oxford, England) 20(1):175\u2013179","journal-title":"Human Reprod (Oxford, England)"},{"issue":"5","key":"6549_CR78","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1089\/met.2011.0019","volume":"9","author":"I Anaforoglu","year":"2011","unstructured":"Anaforoglu I, Algun E, Incecayir O, Ersoy K (2011) Higher metabolic risk with national institutes of health versus Rotterdam diagnostic criteria for polycystic ovarian syndrome in Turkish women. Metab Syndr Relat Disord 9(5):375\u2013380","journal-title":"Metab Syndr Relat Disord"},{"issue":"1","key":"6549_CR79","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0015-0282(01)02941-7","volume":"77","author":"M Kocak","year":"2002","unstructured":"Kocak M, Caliskan E, Simsir C, Haberal A (2002) Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril 77(1):101\u2013106","journal-title":"Fertil Steril"},{"issue":"2","key":"6549_CR80","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.fertnstert.2019.04.013","volume":"112","author":"S Lingaiah","year":"2019","unstructured":"Lingaiah S, Morin-Papunen L, Risteli J, Tapanainen JS (2019) Metformin decreases bone turnover markers in polycystic ovary syndrome: a post hoc study. Fertil Steril 112(2):362\u2013370","journal-title":"Fertil Steril"},{"issue":"7","key":"6549_CR81","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/j.1471-0528.2006.00966.x","volume":"113","author":"J Lord","year":"2006","unstructured":"Lord J, Thomas R, Fox B, Acharya U, Wilkin T (2006) The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome\u2013a randomised, double-blind, placebo-controlled trial. BJOG: Int J Obstet Gynaecol 113(7):817\u2013824","journal-title":"BJOG: Int J Obstet Gynaecol"},{"issue":"8","key":"6549_CR82","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/humrep\/16.8.1625","volume":"16","author":"EH Ng","year":"2001","unstructured":"Ng EH, Wat NM, Ho PC (2001) Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Human Reprod (Oxford, England) 16(8):1625\u20131631","journal-title":"Human Reprod (Oxford, England)"},{"issue":"8","key":"6549_CR83","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1210\/jc.2007-0441","volume":"92","author":"S Palomba","year":"2007","unstructured":"Palomba S, Falbo A, Russo T et al (2007) Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 92(8):3128\u20133135","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"6549_CR84","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1016\/j.fertnstert.2010.01.057","volume":"94","author":"B Trolle","year":"2010","unstructured":"Trolle B, Lauszus FF, Frystyk J, Flyvbjerg A (2010) Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study. Fertil Steril 94(6):2234\u20132238","journal-title":"Fertil Steril"},{"issue":"2","key":"6549_CR85","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S0015-0282(00)01675-7","volume":"75","author":"DT Vandermolen","year":"2001","unstructured":"Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE (2001) Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 75(2):310\u2013315","journal-title":"Fertil Steril"},{"issue":"2","key":"6549_CR86","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/humrep\/17.2.289","volume":"17","author":"H Yarali","year":"2002","unstructured":"Yarali H, Yildiz BO, Demirol A et al (2002) Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reprod (Oxford, England) 17(2):289\u2013294","journal-title":"Human Reprod (Oxford, England)"},{"issue":"10","key":"6549_CR87","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/humrep\/16.10.2066","volume":"16","author":"L Ciotta","year":"2001","unstructured":"Ciotta L, Calogero AE, Farina M, De Leo V, La Marca A, Cianci A (2001) Clinical, endocrine and metabolic effects of acarbose, an alpha-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance. Human Reprod (Oxford, England) 16(10):2066\u20132072","journal-title":"Human Reprod (Oxford, England)"},{"issue":"1","key":"6549_CR88","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1210\/jcem-63-1-119","volume":"63","author":"J Buvat","year":"1986","unstructured":"Buvat J, Buvat-Herbaut M, Marcolin G et al (1986) A double blind controlled study of the hormonal and clinical effects of bromocriptine in the polycystic ovary syndrome. J Clin Endocrinol Metab 63(1):119\u2013124","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6549_CR89","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1471-0528.1987.tb03105.x","volume":"94","author":"AP Murdoch","year":"1987","unstructured":"Murdoch AP, McClean KG, Watson MJ, Dunlop W, Kendall TP (1987) Treatment of hirsutism in polycystic ovary syndrome with bromocriptine. Br J Obstet Gynaecol 94(4):358\u2013365","journal-title":"Br J Obstet Gynaecol"},{"issue":"8","key":"6549_CR90","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1210\/jc.2003-031737","volume":"89","author":"N Brettenthaler","year":"2004","unstructured":"Brettenthaler N, De Geyter C, Huber PR, Keller U (2004) Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 89(8):3835\u20133840","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6549_CR91","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.fertnstert.2005.12.067","volume":"86","author":"D Glintborg","year":"2006","unstructured":"Glintborg D, Hermann AP, Andersen M et al (2006) Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertil Steril 86(2):385\u2013397","journal-title":"Fertil Steril"},{"issue":"10","key":"6549_CR92","doi-asserted-by":"publisher","first-page":"5605","DOI":"10.1210\/jc.2005-0615","volume":"90","author":"D Glintborg","year":"2005","unstructured":"Glintborg D, St\u00f8ving RK, Hagen C et al (2005) Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. J Clin Endocrinol Metab 90(10):5605\u20135612","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6549_CR93","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1365-2265.2004.01973.x","volume":"60","author":"A Gambineri","year":"2004","unstructured":"Gambineri A, Pelusi C, Genghini S et al (2004) Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol 60(2):241\u2013249","journal-title":"Clin Endocrinol"},{"issue":"6","key":"6549_CR94","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/humrep\/dei505","volume":"21","author":"K Rautio","year":"2006","unstructured":"Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC (2006) Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Human Reprod (Oxford, England) 21(6):1400\u20131407","journal-title":"Human Reprod (Oxford, England)"},{"issue":"1","key":"6549_CR95","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.fertnstert.2010.06.058","volume":"95","author":"KK Naka","year":"2011","unstructured":"Naka KK, Kalantaridou SN, Kravariti M et al (2011) Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 95(1):203\u2013209","journal-title":"Fertil Steril"},{"issue":"3","key":"6549_CR96","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1210\/jc.2004-1965","volume":"90","author":"C Ortega-Gonz\u00e1lez","year":"2005","unstructured":"Ortega-Gonz\u00e1lez C, Luna S, Hern\u00e1ndez L et al (2005) Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 90(3):1360\u20131365","journal-title":"J Clin Endocrinol Metab"},{"key":"6549_CR97","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13048-015-0161-3","volume":"8","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A (2015) Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res 8:32","journal-title":"J Ovarian Res"},{"issue":"4","key":"6549_CR98","doi-asserted-by":"publisher","first-page":"402.e401","DOI":"10.1016\/j.ajog.2006.12.025","volume":"196","author":"RS Legro","year":"2007","unstructured":"Legro RS, Zaino RJ, Demers LM et al (2007) The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 196(4):402.e401-410","journal-title":"Am J Obstet Gynecol"},{"key":"6549_CR99","first-page":"70","volume":"65","author":"M Jensterle","year":"2016","unstructured":"Jensterle M, Kravos N, Jane\u017e A (2016) Short-term effectiveness of low dose liraglutide in combination with metformin vs. high dose liraglutide alone in treatment of obesity. Diabetes. 65:70","journal-title":"Diabetes."},{"issue":"1","key":"6549_CR100","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12902-017-0155-9","volume":"17","author":"M Jensterle","year":"2017","unstructured":"Jensterle M, Kravos NA, Goricar K, Janez A (2017) Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord 17(1):5","journal-title":"BMC Endocr Disord"},{"issue":"6","key":"6549_CR101","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/cen.13454","volume":"87","author":"X Liu","year":"2017","unstructured":"Liu X, Zhang Y, Zheng SY et al (2017) Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight\/obese polycystic ovary syndrome. Clin Endocrinol 87(6):767\u2013774","journal-title":"Clin Endocrinol"},{"issue":"1","key":"6549_CR102","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12902-018-0243-5","volume":"18","author":"T Tao","year":"2018","unstructured":"Tao T, Wu P, Wang Y, Liu W (2018) Comparison of glycemic control and \u03b2-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment. BMC Endocr Disord 18(1):14","journal-title":"BMC Endocr Disord"},{"issue":"8","key":"6549_CR103","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40618-014-0103-8","volume":"37","author":"D Glintborg","year":"2014","unstructured":"Glintborg D, Mumm H, Altinok ML, Richelsen B, Bruun JM, Andersen M (2014) Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and\/or oral contraceptives in polycystic ovary syndrome. J Endocrinol Invest 37(8):757\u2013764","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"6549_CR104","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.metabol.2015.06.011","volume":"64","author":"D Glintborg","year":"2015","unstructured":"Glintborg D, Sidelmann JJ, Altinok ML, Mumm H, Andersen M (2015) Increased thrombin generation in women with polycystic ovary syndrome: a pilot study on the effect of metformin and oral contraceptives. Metab Clin Exp 64(10):1272\u20131278","journal-title":"Metab Clin Exp"},{"issue":"9","key":"6549_CR105","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.1210\/jc.2003-030424","volume":"88","author":"L Harborne","year":"2003","unstructured":"Harborne L, Fleming R, Lyall H, Sattar N, Norman J (2003) Metformin or anti-androgen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 88(9):4116\u20134123","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"6549_CR106","doi-asserted-by":"publisher","first-page":"551","DOI":"10.4103\/jfmpc.jfmpc_83_17","volume":"7","author":"Y Kumar","year":"2018","unstructured":"Kumar Y, Kotwal N, Singh Y, Upreti V, Somani S, Hari Kumar KVS (2018) A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. J Fam Med Prim Care 7(3):551\u2013556","journal-title":"J Fam Med Prim Care"},{"issue":"1","key":"6549_CR107","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1210\/jc.2002-020997","volume":"88","author":"L Morin-Papunen","year":"2003","unstructured":"Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS (2003) Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 88(1):148\u2013156","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"6549_CR108","first-page":"3161","volume":"85","author":"LC Morin-Papunen","year":"2000","unstructured":"Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS (2000) Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 85(9):3161\u20133168","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6549_CR109","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/humrep\/deh588","volume":"20","author":"D Cibula","year":"2005","unstructured":"Cibula D, Fanta M, Vrbikova J et al (2005) The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reprod (Oxford, England) 20(1):180\u2013184","journal-title":"Human Reprod (Oxford, England)"},{"issue":"7","key":"6549_CR110","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/humrep\/17.7.1729","volume":"17","author":"K Elter","year":"2002","unstructured":"Elter K, Imir G, Durmusoglu F (2002) Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reprod (Oxford, England) 17(7):1729\u20131737","journal-title":"Human Reprod (Oxford, England)"},{"issue":"6","key":"6549_CR111","first-page":"663","volume":"23","author":"HY Malkawi","year":"2002","unstructured":"Malkawi HY, Qublan HS (2002) The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene-resistant women with polycystic ovary syndrome. Saudi Med J 23(6):663\u2013666","journal-title":"Saudi Med J"},{"issue":"2","key":"6549_CR112","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00404-014-3217-5","volume":"290","author":"K Kahraman","year":"2014","unstructured":"Kahraman K, S\u00fck\u00fcr YE, Atabeko\u011flu CS et al (2014) Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial. Arch Gynecol Obstet 290(2):321\u2013328","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"6549_CR113","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.fertnstert.2005.09.030","volume":"85","author":"AJ Duleba","year":"2006","unstructured":"Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L (2006) Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertil Steril 85(4):996\u20131001","journal-title":"Fertil Steril"},{"issue":"4","key":"6549_CR114","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/09513599709152542","volume":"11","author":"L Falsetti","year":"1997","unstructured":"Falsetti L, De Fusco D, Eleftheriou G, Rosina B (1997) Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome. Gynecol Endocrinol: Off J Int Soc Gynecol Endocrinol 11(4):251\u2013257","journal-title":"Gynecol Endocrinol: Off J Int Soc Gynecol Endocrinol"},{"issue":"4","key":"6549_CR115","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1530\/eje.0.1410361","volume":"141","author":"L Falsetti","year":"1999","unstructured":"Falsetti L, Gambera A, Legrenzi L, Iacobello C, Bugari G (1999) Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol 141(4):361\u2013367","journal-title":"Eur J Endocrinol"},{"key":"6549_CR116","doi-asserted-by":"publisher","first-page":"5150684","DOI":"10.1155\/2020\/5150684","volume":"2020","author":"Y Guan","year":"2020","unstructured":"Guan Y, Wang D, Bu H, Zhao T, Wang H (2020) The effect of metformin on polycystic ovary syndrome in overweight women: a systematic review and meta-analysis of randomized controlled trials. Int J Endocrinol 2020:5150684","journal-title":"Int J Endocrinol"},{"issue":"4","key":"6549_CR117","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/cen.14013","volume":"91","author":"H Teede","year":"2019","unstructured":"Teede H, Tassone EC, Piltonen T et al (2019) Effect of the combined oral contraceptive pill and\/or metformin in the management of polycystic ovary syndrome: a systematic review with meta-analyses. Clin Endocrinol (Oxf) 91(4):479\u2013489","journal-title":"Clin Endocrinol (Oxf)"},{"key":"6549_CR118","first-page":"CD05552","volume":"8","author":"E Fraison","year":"2020","unstructured":"Fraison E, Kostova E, Moran LJ et al (2020) Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome. Cochrane Database Syst Rev 8:CD05552","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"6549_CR119","doi-asserted-by":"publisher","first-page":"bvaa155","DOI":"10.1210\/jendso\/bvaa155","volume":"5","author":"RA Al Khalifah","year":"2021","unstructured":"Al Khalifah RA, Florez ID, Zoratti MJ, Dennis B, Thabane L, Bassilious E (2021) Efficacy of treatments for polycystic ovarian syndrome management in adolescents. J Endocr Soc 5(1):bvaa155","journal-title":"J Endocr Soc"},{"issue":"3","key":"6549_CR120","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1365-2265.2010.03917.x","volume":"74","author":"XJ Li","year":"2011","unstructured":"Li XJ, Yu YX, Liu CQ et al (2011) Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. Clin Endocrinol (Oxf) 74(3):332\u2013339","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"6549_CR121","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1055\/s-2003-39056","volume":"35","author":"KH Chou","year":"2003","unstructured":"Chou KH, von Eye Corleta H, Capp E, Spritzer PM (2003) Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Horm Metab Res = Hormon- und Stoffwechselforschung = Hormones et Metabolisme 35(2):86\u201391","journal-title":"Horm Metab Res = Hormon- und Stoffwechselforschung = Hormones et Metabolisme"},{"issue":"2","key":"6549_CR122","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2337\/dc07-1424","volume":"31","author":"D Glintborg","year":"2008","unstructured":"Glintborg D, H\u00f8jlund K, Andersen M, Henriksen JE, Beck-Nielsen H, Handberg A (2008) Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diab Care 31(2):328\u2013334","journal-title":"Diab Care"},{"key":"6549_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-015-0161-3","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Salamun V, Kocjan T, Bokal EV, Janez A (2015) Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. Endoc Rev. https:\/\/doi.org\/10.1186\/s13048-015-0161-3 (Janez A. University Medical Center Ljubljana, Ljubljana, Slovenia)","journal-title":"Endoc Rev"},{"issue":"1","key":"6549_CR124","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12902-017-0155-9","volume":"17","author":"M Jensterle","year":"2017","unstructured":"Jensterle M, Kravos NA, Gori\u010dar K, Janez A (2017) Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord 17(1):5","journal-title":"BMC Endocr Disord"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06549-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-022-06549-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06549-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T05:36:49Z","timestamp":1681796209000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-022-06549-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":124,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["6549"],"URL":"https:\/\/doi.org\/10.1007\/s00404-022-06549-6","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,18]]},"assertion":[{"value":"4 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"It was not needed as no patients were involved.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}